V3V Share Price Performance
€5.05
0.55 (12.22%)
Price €5.05
Share Price€5.05
V3V Community Narratives
There are no narratives available yet.
Recent V3V News & Updates
No updates
FamiCord AG Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 27, 2025
- Earnings per share (EPS)
- -0.69
- Gross Margin
- 26.15%
- Net Profit Margin
- -14.02%
- Debt/Equity Ratio
- 47.5%
FamiCord AG Competitors
About V3V
- Founded
- 1997
- Employees
- 766
- CEO
- WebsiteView website
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is based in Leipzig, Germany.
German Market Performance
- 7 Days: 0.3%
- 3 Months: -4.8%
- 1 Year: 23.4%
- Year to Date: 4.4%
The Materials sector gained 6.2% while the market remained flat over the last week. More promisingly, the market is up 23% over the past year. Looking forward, earnings are forecast to grow by 17% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading